Chemed Corporation (CHE) — insider trading
Health Care · NYSE
Chemed Corporation (CHE) has 33 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 33 (latest 2026-09-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | LEE SPENCER S | Officer (executive vice president) | Option exercise / conversion (derivative) | 12,099 | $445.35 | $5.39M | Form 4 |
| 2026-09-30 | LEE SPENCER S | Officer (executive vice president) | Shares withheld for taxes / exercise cost | 11,160 | $508.93 | $5.68M | Form 4 |
| 2026-09-30 | LEE SPENCER S | Officer (executive vice president) | Option exercise / conversion | 12,099 | $445.35 | $5.39M | Form 4 |
| 2026-09-28 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Open-market sale | 2,000 | $513.45 | $1.03M | Form 4 |
| 2026-09-28 | HUTTON THOMAS C | Director, Officer (vice president) | Option exercise / conversion (derivative) | 4,629 | $445.35 | $2.06M | Form 4 |
| 2026-09-28 | HUTTON THOMAS C | Director, Officer (vice president) | Shares withheld for taxes / exercise cost | 4,270 | $506.65 | $2.16M | Form 4 |
| 2026-09-28 | HUTTON THOMAS C | Director, Officer (vice president) | Option exercise / conversion | 4,629 | $445.35 | $2.06M | Form 4 |
| 2026-09-18 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Open-market sale | 2,000 | $501.40 | $1.00M | Form 4 |
| 2026-08-21 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Open-market sale | 2,000 | $541.16 | $1.08M | Form 4 |
| 2026-08-21 | LEE SPENCER S | Officer (executive vice president) | Open-market sale | 1,000 | $541.04 | $541.0K | Form 4 |
| 2026-08-10 | Judkins Brian C | Officer (VP and Chief Legal Officer) | Option exercise / conversion (derivative) | 6,786 | $445.35 | $3.02M | Form 4 |
| 2026-08-10 | Judkins Brian C | Officer (VP and Chief Legal Officer) | Shares withheld for taxes / exercise cost | 5,878 | $548.96 | $3.23M | Form 4 |
| 2026-08-10 | Judkins Brian C | Officer (VP and Chief Legal Officer) | Option exercise / conversion | 6,786 | $445.35 | $3.02M | Form 4 |
| 2026-08-05 | Wherley Joel L | Officer (CEO - Vitas Healthcare) | Option exercise / conversion (derivative) | 2,599 | $445.35 | $1.16M | Form 4 |
| 2026-08-05 | Wherley Joel L | Officer (CEO - Vitas Healthcare) | Shares withheld for taxes / exercise cost | 2,270 | $542.62 | $1.23M | Form 4 |
| 2026-08-05 | Wherley Joel L | Officer (CEO - Vitas Healthcare) | Option exercise / conversion | 2,599 | $445.35 | $1.16M | Form 4 |
| 2026-08-03 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Option exercise / conversion (derivative) | 2,001 | $445.35 | $891.1K | Form 4 |
| 2026-08-03 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Open-market sale | 2,000 | $539.51 | $1.08M | Form 4 |
| 2026-07-31 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Shares withheld for taxes / exercise cost | 19,802 | $529.22 | $10.48M | Form 4 |
| 2026-07-31 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Option exercise / conversion | 2,001 | $445.35 | $891.1K | Form 4 |
| 2026-07-31 | GRACE PATRICK P | Director | Open-market sale | 190 | $532.00 | $101.1K | Form 4 |
| 2026-06-09 | LINDELL ANDREA R | Director | Open-market sale | 1,347 | $447.33 | $602.6K | Form 4 |
| 2026-05-29 | WALSH GEORGE J III | Director | Open-market sale | 500 | $437.83 | $218.9K | Form 4 |
| 2026-05-18 | DeLyons Ron | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-18 | GRACE PATRICK P | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-18 | Heaney Christopher J | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-18 | LINDELL ANDREA R | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-18 | McCarthy Eileen P | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-18 | Mount John Meredith Jr. | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-18 | WALSH GEORGE J III | Director | Grant / award / vesting | 386 | $440.77 | $170.1K | Form 4 |
| 2026-05-08 | GRACE PATRICK P | Director | Open-market sale | 60 | $425.78 | $25.5K | Form 4 |
| 2026-05-01 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Open-market sale | 2,000 | $421.13 | $842.3K | Form 4 |
| 2026-03-27 | MCNAMARA KEVIN J | Director, Officer (president and CEO) | Open-market sale | 1,500 | $369.37 | $554.1K | Form 4 |
Ask the chat about CHE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Chemed Corporation (CHE).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.